Lucentis

Lucentis

ranibizumab

Manufacturer:

Novartis Pharma Stein

Distributor:

Novartis Healthcare
Concise Prescribing Info
Contents
Ranibizumab
Indications/Uses
Neovascular (wet) age-related macular degeneration (AMD); proliferative diabetic retinopathy (PDR); visual impairment due to choroidal neovascularization (CNV); visual impairment due to CNV secondary to pathologic myopia (PM); visual impairment due to diabetic macular edema (DME); visual impairment due to macular edema secondary to retinal vein occlusion (branch or central RVO) in adults. Retinopathy of prematurity (ROP) in premature infants.
Dosage/Direction for Use
Interval between 2 doses inj into the same eye should not be shorter than 1 mth.  Adult Recommended dose: 0.5 mg (0.05 mL) as a single intravitreal inj. Wet AMD, DME, PDR, macular edema secondary to RVO, CNV or CNV secondary to PM 1 inj/mth until max visual acuity is achieved &/or there are no signs of disease activity. May be extended by 2 wk at a time for wet AMD & central RVO or by 1 mth at a time for DME & branch RVO when applying treat-&-extend regimen. Administer at least 30 min after laser photocoagulation in DME or branch RVO. Preterm infants Recommended dose: 0.2 mg (0.02 mL) as a single intravitreal inj.
Contraindications
Hypersensitivity. Active or suspected ocular or periocular infections; active intraocular inflammation.
Special Precautions
Endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear & iatrogenic traumatic cataract during intravitreal inj. Monitor patient during the wk following the inj to permit early treatment if an infection occurs. Transient increases in IOP w/in 60 min of inj. Monitor & manage appropriately the IOP & optic nerve perfusion. Risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. Patients w/ known risk factors for stroke, history of prior stroke or transient ischemic attack; potential for immunogenicity. Patients w/ active systemic infections or concurrent eye conditions eg, retinal detachment or macular hole. Females of reproductive potential should use effective contraception during treatment & wait at least 3 mth after the last dose before conceiving a child. May affect ability to drive or use machines. Pregnancy & lactation. Not recommended for childn & adolescents <18 yr.
Adverse Reactions
Nasopharyngitis; headache; intraocular inflammation, vitritis, vitreous detachment, retinal haemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival haemorrhage, eye irritation, foreign body sensation in eyes, increased lacrimation, blepharitis, dry eye, ocular hyperaemia, eye pruritus; arthralgia; increased IOP. Flu, UTI; anaemia; anxiety; stroke; retinal degeneration/disorder, retinal detachment/tear/pigment epithelium tear, detachment of retinal pigment epithelium, reduced visual acuity, vitreous haemorrhage/disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior cap opacification, punctuate keratitis, corneal abrasion, anterior chamber flare, blurred vision, inj site/eye haemorrhage, conjunctivitis, allergic conjunctivitis, eye discharge, photopsia, photophobia, ocular discomfort, eyelid oedema/pain, conjunctival hyperaemia; cough; nausea; allergic reactions (rash, urticaria, pruritus, erythema).
MIMS Class
Other Eye Preparations
ATC Classification
S01LA04 - ranibizumab ; Belongs to the class antineovasculatisation agents. Used in the management of neovascular macular degeneration.
Presentation/Packing
Form
Lucentis soln for inj 10 mg/mL
Packing/Price
(+ syringe) 2 mL x 1's (P24,426/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in